Zkusit zdarma
NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V.

NAMS
Cena:
$ 35.44
-0.30 (-0.84%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

15:00 13-05-2026

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 202...

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

8:41 11-05-2026

NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript

NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript

20:03 09-05-2026

NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis P...

NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends

NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends

16:12 08-05-2026

NewAmsterdam Pharma NASDAQ: NAMS said it plans to conduct an interim analysis of its ongoing PREVAIL...

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates

9:56 07-05-2026

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.4 per share versus the ...

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

7:00 07-05-2026

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/e...

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

8:00 08-04-2026

NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N...

Financial Comparison: NewAmsterdam Pharma (NASDAQ:NAMS) and Shineco (NASDAQ:SISI)

Financial Comparison: NewAmsterdam Pharma (NASDAQ:NAMS) and Shineco (NASDAQ:SISI)

1:57 07-04-2026

NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Shineco (NASDAQ: SISI - Get Free Report) ar...

Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

3:07 06-04-2026

Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 10.2% dur...

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

8:00 23-03-2026

NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N...

NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 101,409 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 101,409 Shares

4:33 10-03-2026

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kaste...

NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 104,467 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 104,467 Shares

4:32 10-03-2026

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kaste...

NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 94,124 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 94,124 Shares of Stock

4:32 10-03-2026

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kaste...

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

7:00 18-02-2026

-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetim...

NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit

NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit

1:02 16-02-2026

NewAmsterdam Pharma (NASDAQ: NAMS) Chief Financial Officer Ian Somaiya said the company remains enco...

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

8:00 04-02-2026

NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N....

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 34,400 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 34,400 Shares of Stock

5:35 28-01-2026

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CAO Louise Frederika Kooij sold 34...

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 38,172 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 38,172 Shares of Stock

5:34 28-01-2026

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CAO Louise Frederika Kooij sold 38...

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

8:00 09-01-2026

-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26...

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares

5:48 30-12-2025

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CAO Louise Frederika Kooij sold 43...

close

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

06-02-2026
NAARDEN, THE NETHERLANDS AND MIAMI, FEB. 06, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

NEWAMSTERDAM PHARMA TO PRESENT AT THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT

04-02-2026
NAARDEN, THE NETHERLANDS AND MIAMI, FEB. 04, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

NEWAMSTERDAM PHARMA HIGHLIGHTS 2025 ACHIEVEMENTS AND OUTLINES 2026 STRATEGIC PRIORITIES

09-01-2026
-- EMA APPROVAL DECISION FOR OBICETRAPIB AND OBICETRAPIB/EZETIMIBE FIXED DOSE COMBO EXPECTED IN 2H26...
Více zde

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

05-01-2026
NAARDEN, THE NETHERLANDS AND MIAMI, JAN. 05, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

05-12-2025
NAARDEN, THE NETHERLANDS AND MIAMI, DEC. 05, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

NEWAMSTERDAM PHARMA TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES IN DECEMBER

25-11-2025
NAARDEN, THE NETHERLANDS AND MIAMI, NOV. 25, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

07-11-2025
NAARDEN, THE NETHERLANDS AND MIAMI, NOV. 07, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

NEWAMSTERDAM PHARMA PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER FINANCIAL RESULTS

05-11-2025
– MARKETING AUTHORIZATION APPLICATIONS FOR OBICETRAPIB AND FDC OF OBICETRAPIB PLUS EZETIMIBE ACCEP...
Více zde

NEWAMSTERDAM PHARMA TO PARTICIPATE IN UPCOMING MEDICAL MEETING AND INVESTOR CONFERENCES IN NOVEMBER

30-10-2025
NAARDEN, THE NETHERLANDS AND MIAMI, OCT. 30, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

ENTERA BIO TO PRESENT NEW CLINICAL DATA FROM PHASE 2 TRIAL OF EB613 AT THE 2025 NORTH AMERICAN MENOPAUSE SOCIETY (NAMS) ANNUAL MEETING

16-10-2025
FIRST-TIME PRESENTATION EXAMINING BONE OUTCOMES IN EARLY POSTMENOPAUSAL WOMEN FIRST-TIME PRESENTATIO...
Více zde

NEWAMSTERDAM PHARMA TO PRESENT AT THE STIFEL 2025 VIRTUAL CARDIOMETABOLIC FORUM

24-09-2025
NAARDEN, THE NETHERLANDS AND MIAMI, SEPT. 24, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N...
Více zde

NEWAMSTERDAM PHARMA TO PARTICIPATE IN UPCOMING MEDICAL MEETING AND INVESTOR CONFERENCES IN SEPTEMBER

25-08-2025
NAARDEN, THE NETHERLANDS AND MIAMI, AUG. 25, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

PIRAMAL PHARMA SOLUTIONS AND NEWAMSTERDAM PHARMA INVEST IN DEDICATED SUITE TO ENHANCE ORAL SOLID DOSAGE PRODUCTION CAPABILITIES AT PIRAMAL'S SELLERSVILLE, PENNSYLVANIA SITE

21-08-2025
THE MULTI-MILLION-DOLLAR INVESTMENT PROVIDES NEWAMSTERDAM PHARMA WITH COMMERCIAL CAPACITY FOR FIXED ...
Více zde

NEWAMSTERDAM ANNOUNCES ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATIONS FOR REVIEW BY EUROPEAN MEDICINE AGENCY FOR OBICETRAPIB

18-08-2025
-- FILINGS BOTH FOR THE OBICETRAPIB MONOTHERAPY AND OBICETRAPIB PLUS EZETIMIBE FIXED-DOSE COMBINATIO...
Více zde

NEWAMSTERDAM PHARMA PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER FINANCIAL RESULTS

06-08-2025
–EUROPEAN MARKETING AUTHORIZATION APPLICATION ON TRACK IN 2H25 –  – PREVAIL PHASE 3 CVOT REMA...
Více zde

NEWAMSTERDAM PHARMA PRESENTS POSITIVE DATA FROM BROADWAY TRIAL DEMONSTRATING STATISTICALLY SIGNIFICANT REDUCTIONS IN KEY ALZHEIMER'S DISEASE BIOMARKERS AT AAIC 2025

30-07-2025
-- PRE-SPECIFIED ANALYSIS SHOWS OBICETRAPIB SIGNIFICANTLY REDUCED ABSOLUTE LEVELS OF PLASMA P-TAU217...
Více zde

NEWAMSTERDAM PHARMA TO PRESENT ALZHEIMER'S BIOMARKER DATA FROM BROADWAY TRIAL AT AAIC 2025

22-07-2025
NAARDEN, THE NETHERLANDS AND MIAMI, JULY 22, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

NEWAMSTERDAM PHARMA ANNOUNCES POSITIVE TOPLINE ALZHEIMER'S DISEASE DATA FROM BROADWAY CLINICAL TRIAL

09-06-2025
-- PRE-SPECIFIED ANALYSES SHOW THAT OBICETRAPIB TREATMENT LEADS TO STATISTICALLY SIGNIFICANT AND CLI...
Více zde

NEWAMSTERDAM PHARMA TO HOST R&D DAY ON JUNE 11, 2025

05-06-2025
NAARDEN, THE NETHERLANDS AND MIAMI, JUNE 05, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

NEWAMSTERDAM PHARMA TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES IN JUNE

27-05-2025
NAARDEN, THE NETHERLANDS AND MIAMI, MAY 27, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V...
Více zde

NEWAMSTERDAM PHARMA TO PRESENT AT THE 2025 RBCCM GLOBAL HEALTHCARE CONFERENCE

14-05-2025
NAARDEN, THE NETHERLANDS AND MIAMI, MAY 14, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V...
Více zde

NEWAMSTERDAM PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER FINANCIAL RESULTS

08-05-2025
– EMA SUBMISSION EXPECTED IN 2H25 BY PARTNER MENARINI – – PREVAIL PHASE 3 CVOT REMAINS ON TRAC...
Více zde

NEWAMSTERDAM PHARMA ANNOUNCES LATE-BREAKING DATA FROM BROADWAY AND TANDEM PIVOTAL STUDIES PUBLISHED IN LEADING MEDICAL JOURNALS AND PRESENTED AT THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) CONGRESS 2025

07-05-2025
– LATE BREAKING BROADWAY AND TANDEM DATA PRESENTED AT EAS 2025 AND SIMULTANEOUSLY PUBLISHED IN THE...
Více zde

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

02-05-2025
NAARDEN, THE NETHERLANDS AND MIAMI, MAY 02, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V...
Více zde

NEWAMSTERDAM PHARMA TO PRESENT NEW CLINICAL AND PRECLINICAL DATA AT 93RD EAS CONGRESS

30-04-2025
PRESENTATIONS INCLUDE NEW DATA FROM BROADWAY AND TANDEM PHASE 3 CLINICAL TRIALS, DEMONSTRATING OBICE...
Více zde

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

04-04-2025
NAARDEN, THE NETHERLANDS AND MIAMI, APRIL 04, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N...
Více zde

NEWAMSTERDAM PHARMA TO PRESENT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

31-03-2025
NAARDEN, THE NETHERLANDS AND MIAMI, MARCH 31, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N...
Více zde

NEWAMSTERDAM PHARMA REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

26-02-2025
-- EMA SUBMISSION EXPECTED IN 2H25 BY PARTNER MENARINI -- -- ADDITIONAL DATA FROM BROADWAY, BROOKLYN...
Více zde

NEWAMSTERDAM PHARMA TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES IN MARCH

25-02-2025
NAARDEN, THE NETHERLANDS AND MIAMI, FEB. 25, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

07-02-2025
NAARDEN, THE NETHERLANDS AND MIAMI, FEB. 07, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N....
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-09 00:00:008-KStáhnout
2025-11-05 00:00:008-KStáhnout
2025-11-05 00:00:0010-QStáhnout
2025-09-02 01:00:008-KStáhnout
2025-09-02 00:00:008-KStáhnout
2025-08-18 01:00:008-KStáhnout
2025-08-18 00:00:008-KStáhnout
2025-08-15 01:00:008-KStáhnout
2025-08-15 00:00:008-KStáhnout
2025-08-06 01:00:008-KStáhnout
2025-08-06 01:00:0010-QStáhnout
2025-08-06 00:00:008-KStáhnout
2025-08-06 00:00:0010-QStáhnout
2025-07-30 01:00:008-KStáhnout
2025-07-30 00:00:008-KStáhnout
2025-07-11 01:00:008-KStáhnout
2025-07-11 00:00:008-KStáhnout
2025-06-11 01:00:008-KStáhnout
2025-06-11 00:00:008-KStáhnout
2025-06-09 01:00:008-KStáhnout
2025-06-09 00:00:008-KStáhnout
2025-06-06 01:00:008-KStáhnout
2025-06-06 00:00:008-KStáhnout
2025-05-08 01:00:008-KStáhnout
2025-05-08 01:00:0010-QStáhnout
2025-05-08 00:00:008-KStáhnout
2025-05-08 00:00:0010-QStáhnout
2025-05-07 01:00:008-KStáhnout
2025-05-07 00:00:008-KStáhnout
2025-04-17 01:00:008-KStáhnout
2025-04-17 00:00:008-KStáhnout
2025-02-26 00:00:008-KStáhnout
2025-02-26 00:00:0010-KStáhnout
2025-02-25 23:00:008-KStáhnout
2025-02-25 23:00:0010-KStáhnout
2025-01-10 00:00:008-KStáhnout
2025-01-09 23:00:008-KStáhnout
2024-12-13 00:00:008-KStáhnout
2024-12-12 23:00:008-KStáhnout
2024-12-10 00:00:008-KStáhnout
2024-12-09 23:00:008-KStáhnout
2024-11-20 00:00:008-KStáhnout
2024-11-19 23:00:008-KStáhnout
2024-11-18 00:00:008-KStáhnout
2024-11-17 23:00:008-KStáhnout
2024-11-06 00:00:008-KStáhnout
2024-11-06 00:00:0010-QStáhnout
2024-11-05 23:00:008-KStáhnout
2024-11-05 23:00:0010-QStáhnout
2024-10-18 01:00:008-KStáhnout
2024-10-18 00:00:008-KStáhnout
2024-08-09 01:00:008-KStáhnout
2024-08-09 00:00:008-KStáhnout
2024-08-07 01:00:008-KStáhnout
2024-08-07 01:00:0010-QStáhnout
2024-08-07 00:00:008-KStáhnout
2024-08-07 00:00:0010-QStáhnout
2024-07-29 01:00:008-KStáhnout
2024-07-29 00:00:008-KStáhnout
2024-07-18 01:00:008-KStáhnout
2024-07-18 00:00:008-KStáhnout
2024-06-11 01:00:008-KStáhnout
2024-06-11 00:00:008-KStáhnout
2024-06-07 01:00:008-KStáhnout
2024-06-07 00:00:008-KStáhnout
2024-05-09 01:00:008-KStáhnout
2024-05-09 00:00:008-KStáhnout
2024-05-08 01:00:0010-QStáhnout
2024-05-08 00:00:0010-QStáhnout
2024-04-01 01:00:008-KStáhnout
2024-04-01 00:00:008-KStáhnout
2024-03-04 00:00:008-KStáhnout
2024-03-03 23:00:008-KStáhnout
2024-02-28 00:00:008-KStáhnout
2024-02-28 00:00:0010-KStáhnout
2024-02-27 23:00:008-KStáhnout
2024-02-27 23:00:0010-KStáhnout
2024-02-15 00:00:008-KStáhnout
2024-02-14 23:00:008-KStáhnout
2024-01-22 00:00:008-KStáhnout
2024-01-21 23:00:008-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2024-01-04 00:00:008-KStáhnout
2024-01-03 23:00:008-KStáhnout
preloader